Legal Representation
Attorney
Claudia A. Smith
USPTO Deadlines
Next Renewal Deadline
1142 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-08-23)
Due Date
August 23, 2028
Grace Period Ends
February 23, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
18 events| Date | Code | Type | Description |
|---|---|---|---|
| Aug 23, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Aug 23, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Jun 7, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jun 7, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| May 18, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Apr 29, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Apr 7, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Apr 7, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Apr 5, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Oct 5, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Oct 5, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Oct 5, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Sep 22, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
| Sep 10, 2021 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Sep 9, 2021 | ALIE | A | ASSIGNED TO LIE |
| Sep 7, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Jul 12, 2021 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Jun 24, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceuticals and medical preparations and substances; vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disease and disorder, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disease and disorder, insomnia, Parkinson's disease and disorder, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, PSP, restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; preparations, substances, reagents and agents for diagnostic and medical purposes
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005